Medication-related interventions to improve medication safety and patient outcomes on transition from adult intensive care settings: a systematic review and meta-analysis

Richard S Bourne, Jennifer K Jennings, Maria Panagioti, Alexander Hodkinson, Anthea Sutton, Darren M Ashcroft

ABSTRACT

Background Patients recovering from an episode in an intensive care unit (ICU) frequently experience medication errors on transition to the hospital ward. Structured handover recommendations often underestimate the challenges and complexity of ICU patient transitions. For adult ICU patients transitioning to a hospital ward, it is currently unclear what interventions reduce the risks of medication errors. The aims were to examine the impact of medication-related interventions on medication and patient outcomes on transition from adult ICU settings and identify barriers and facilitators to implementation.

Methods The systematic review protocol was preregistered on PROSPERO. Six electronic databases were searched until October 2020 for controlled and uncontrolled study designs that reported medication-related (ie, de-prescribing; medication errors) or patient-related outcomes (ie, mortality; length of stay). Risk of bias (RoB) assessment used V.2.0 and ROBINS-I Cochrane tools. Where feasible, random-effects meta-analysis was used for pooling the OR across studies. The quality of evidence was assessed by Grading of Recommendations, Assessment, Development and Evaluations.

Results Seventeen studies were eligible, 15 (88%) were uncontrolled before-after studies. The intervention components included education of staff (n=8 studies), medication review (n=7), guidelines (n=6), electronic transfer/handover tool or letter (n=4) and medicines reconciliation (n=4). Overall, pooled analysis of all interventions reduced risk of inappropriate medication continuation at ICU discharge (OR=0.45 (95% CI 0.31 to 0.63), I²=55%, n=9) and hospital discharge (OR=0.39 (95% CI 0.2 to 0.76), I²=75%, n=9). Multicomponent interventions, based on education of staff and guidelines, demonstrated no significant difference in inappropriate medication continuation at the ICU discharge point (OR 0.5 (95% CI 0.2 to 1.1), I²=62%, n=4), but were very effective in increasing de-prescribing outcomes on hospital discharge (OR 0.26 (95% CI 0.13 to 0.55), I²=67%, n=6). Facilitators to intervention delivery included ICU clinical pharmacist availability and participation in multiprofessional ward rounds, while barriers included increased workload associated with the discharge intervention process.

Conclusions Multicomponent interventions based on education of staff and guidelines were effective at achieving almost four times more de-prescribing of inappropriate medication by the time of patient hospital discharge. Based on the findings, practice and policy recommendations are made and guidance is provided on the need for, and design of, theory informed interventions in this area, including the requirement for process and economic evaluations.

BACKGROUND

Delivering quality and safety at patient care transitions is challenging and complex, with patient outcomes affected by a wide range of interacting system and process components. Medication safety in transitions of patient care is a key priority area for the third WHO’s Global Patient Safety Challenge—‘medication without harm’. For adult patients surviving an intensive care unit (ICU) care episode, the transition to a hospital ward is especially challenging for care continuity and safety. ICU patients may experience a protracted recovery, further compounded by polypharmacy and care fragmentation. They also encounter frequent medication changes, with many chronic medicines discontinued and acute medication commenced, presenting a patient safety concern, particularly at the point of transitions.

Medication errors (MEs) are common in adult ICU patients at the interface of transfer to the hospital ward, with MEs reported to occur in between 46% and 74% of patients. The most commonly reported types of ME involve continuation of potentially inappropriate
medication, discontinuation of important chronic medication and inappropriate dose or route of administration.\(^{13-15}\) The reported incidence of adverse drug events (ADEs) related to ICU patient transfer varies from 6% to 70%,\(^{13,15,16}\) according to surveillance period and methodology employed, being highest in the intervention study with prospectively collected data.\(^{13}\) MEs post-ICU care can also continue long after patient hospital discharge.\(^{17-20}\) Pre-existing polypharmacy burden may predict ME risk,\(^{21}\) and the risk of unplanned hospital readmission.\(^{22}\)

To mitigate this increased patient safety risk, the European Society of Intensive Care Medicine recommends use of a standardised handover procedure, including an explanation of medication changes and treatment plans, on patient transfer from ICU.\(^{23}\) However, ICU medication-related discharge practices remain inconsistent.\(^{24-27}\) Contributors to variation in practice include uncertainty over key intervention components and processes,\(^{24}\) availability of important medicines optimisation resources\(^{25}\) and staff communication failures\(^{26}\) in the context of an important care interface.\(^{4}\) Moreover, in isolation, the recommended handover procedure does not adequately address the challenges and complexity of patient care transitions including the importance of patient and family engagement, medicines reconciliation and medication review.\(^{1,2,4,6,28}\)

A recent systematic review demonstrated the benefits of pharmacy-led interventions to improve de-prescribing of stress ulceration prophylaxis (SUP) at ICU and hospital discharge points.\(^{29}\) However, a broader scope and multiprofessional approach is required to meet the wider medicines optimisation and communication challenges to transitional medication continuity and safety.\(^{4}\) For ICU patient to hospital ward transitions, it is unclear what medication-related intervention components are required and their efficacy, timing and mode of delivery. This information is required to help optimise existing medicines-related practice for ICU patients on transition to a hospital ward, and aid identification of evidence gaps, informing the need and design of further research to improve patient safety.

This systematic review and meta-analysis aimed to (i) examine the impact of medication-related interventions on medication and patient outcomes on transition from adult ICU settings and (ii) identify barriers and facilitators during intervention implementation.

**METHODS**

We performed a systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement.\(^{30}\) The protocol was preregistered on the international prospective register of systematic reviews (PROSPERO) database (CRD42020210638). Patient and public involvement and engagement was provided by representatives from intensive care and emergency care forums in the scope of review and planned dissemination of results.

**Eligibility criteria**

We included studies conducted in adult (≥18 years old) ICU patients surviving to transition to a hospital ward, investigating any medication-related interventions designed to affect medication continuity, safety or efficacy for ICU patients transitioning to a hospital ward, compared with usual care; that is, a non-exposed control group or historical group in a before-after study, evaluating medication-related (eg, MEs) or patient-related outcomes (eg, length of stay, mortality). Interventions had to be conducted before or within 48 hours of ICU patient transition to the hospital ward. We used the Cochrane Effective Practice and Organisation of Care Group criteria as a guide for study eligibility.\(^{31}\) Randomised controlled trials (RCTs) and non-randomised controlled and uncontrolled trials (including ‘before-after’ and ‘interrupted time series’ designs) were eligible for inclusion. Review articles, studies based on simulation and conference abstracts were excluded.

**Information sources**

In October 2020, the following databases were searched from inception without language restrictions: MEDLINE and MEDLINE Epub Ahead of Print, In-Process and Other Non-Indexed Citations and Daily; EMBASE; CINAHL; International Pharmaceutical Abstracts; The Cochrane Library; Science Citation Index. A search of the trial registries International Clinical Trials Registry Platform and ClinicalTrials.gov was conducted in August 2021 (online supplemental file 1).

**Selection process**

Two independent reviewers (RSB, JKJ) participated in each phase of the selection process. Any disagreement between reviewers was resolved by discussion, with arbitration by a third reviewer (DMA) when required. First, titles and abstracts were screened based on our eligibility criteria. Second, full texts were screened. Finally, reference lists of included studies and any relevant reviews were checked for any further relevant references. The citation search facility in Web of Science was used to identify any relevant cited references and additional studies by key authors. Authors of all eligible abstracts published within the last 2 years were contacted to confirm recent or planned publication.\(^{32-36}\)

**Data extraction**

Two reviewers (RSB, JKJ) independently extracted data in duplicate from included studies using a standardised data extraction form (with cross-checking validation process). The structured data collection form...
was piloted, and data inputted into a proprietary software database (Covidence; www.covidence.org).

Risk of bias in individual studies
Quality assessment of individual studies was done by two independent authors (RSB, JKJ) using the Cochrane risk of bias (RoB) V.2.0 tool for RCTs,35 and ROBINS-I for non-randomised studies.38 Any disagreement was resolved by discussion, with arbitration by a third independent reviewer (MP) when required. RoB judgements are presented using the robvis visualisation tool (www.riskofbias.info/welcome/robvis-visualization-tool). Studies with a ‘high’ or ‘critical’ RoB assessment37 38 were excluded from any meta-analysis.

Confidence in overall evidence using Grading of Recommendations, Assessment, Development and Evaluations
We undertook a Grading of Recommendations, Assessment, Development and Evaluations (GRADE) assessment using the standard five GRADE criteria.39 We used ‘summary of findings’ tables to provide outcome-specific information related to the overall quality of evidence from studies included in comparisons, the magnitude of effect of the interventions examined and the sum of available data on the outcomes we considered.

Data synthesis
Data regarding medication-related interventions were summarised and described separately using the TIDieR framework.40 Barriers and facilitators in the primary research papers were summarised to allow comparison with those already identified.7

Meta-analysis was planned if comparable studies (design and outcome(s) reported) were identified. Before meta-analysis, we transformed data onto the uniform log odds scale using the Comprehensive Meta-Analysis (V.3) software (Biostat, New Jersey, USA). Then for all of the comparable ‘uncontrolled before-and-after studies’ with the relevant outcome data we meta-analysed using the DerSimonian-Laird random-effects model.41 The Hartung-Knapp random-effects method for pooling42 was used instead of DerSimonian-Laird, as it is a more robust method of choice when study sizes are small and there is considerable heterogeneity, as likely to be present in the non-randomised uncontrolled trials identified.

Statistical heterogeneity for assessment of comparability of forest plots was undertaken by visual inspection of forest plots and I² statistic (0%–25% low; ≥25%–75% substantial and ≥75% considerable heterogeneity) with the associated 95% CIs.43 For each meta-analysis with 10 studies or more, funnel plots, Begg’s and Egger’s test were used to examine potential publication bias. The trim-and-fill method was used as a sensitivity analysis to observe cases of small study publication bias.44 We planned subgroup analyses if sufficient data were available for studies with comparable interventions and outcome measures. All meta-analyses were performed in the statistical software R (V.4.0.3) with packages meta45 and metafor.46

RESULTS
Study inclusion
The literature searches identified 3,153 references, after removal of duplicates, abstract and title screening and then assessment of full-text eligibility, 17 studies were included (table 1).13 14 47–61 The publications of Wohlt et al (before)62 and Hatch et al (after)59 were considered as a single study referenced as Hatch et al,59 for the purposes of this systematic review. The PRISMA flow chart for study inclusion is shown figure 1.

Characteristics of included studies
Most of the studies (76%) were from North America (n=12 the USA, n=1 Canada),47–53 55–60 three from Europe (n=2 The Netherlands, n=1 Belgium),13 14 61 and one from Australia54 (table 1). Only the study by Heselmans et al44 was an RCT, 15 were uncontrolled before-after studies13 47–49 51–61 and one was an uncontrolled interrupted time-series analyses.50 Most studies (n=14, 82%) were conducted in single centres, three were multicentre studies.13 14 54 Approximately one-third of the studies (n=6, 35%) were prospective in data collection and evaluation.13 14 47 50 54 56 61 Interventions are fully described according to the TIDieR framework (online supplemental table S1).40

Characteristics of interventions
Intervention components
Nine (53%) of the studies examined a single intervention component (table 1 and online supplemental table S1).44 47–50 52 55 56 61 The key intervention components described were education of staff, medication review, guidelines, electronic transfer/hand-over checklist or letter and medicines reconciliation. Multicomponent interventions,51 53 54 57–59 targeted inappropriate medication continuation at transfer points. These were based on education of staff and guidelines, with three studies also including a medication review element.51 53 54

Education of staff
Education of staff was an intervention component in eight studies (47%).47 51 53 54 57–60 Studies varied by healthcare professionals the education was targeted at. Uniprofessional,47 53 54 58 60 educational approaches were more commonly employed than multiprofessional.51 57 59 Mode of and frequency of delivery varied across the studies (table 1 and online supplemental table S1).

Bourne RS, et al. BMJ Qual Saf 2022;0:1–14. doi:10.1136/bmjqs-2021-013760
**Table 1** Summary of study characteristics

| Study/Country | Study design/centres (number) | Intervention target | Participants | Participant numbers (control/before: intervention/after) | Intervention description, (components) and (timing) |
|---------------|------------------------------|---------------------|--------------|----------------------------------------------------------|-------------------------------------------------|
| Anstey et al Australia[^54] | Before-after (B-A); prospective; multi (n=5) | De-escalation of inappropriate stress ulcer prophylaxis (SUP) | Adult intensive care unit (ICU) patients (medical, surgical, cardiothoracic) Inclusion: consecutive ICU patients admitted during the active study period Exclusion: patients <18 years of age | 842 (469: 373) | SUP de-escalation bundle (education of ICU medical staff; guidelines; pharmacist-led prescription discontinue) (ICU stay) |
| Bosma et al Netherlands[^13] | B-A; prospective; multi (n=2) | Medication errors (MEs) on ICU discharge | Adult ICU patients (medical, surgical, neurosurgery, cardiology) Inclusion: patients admitted on ≥1 regular medicine with ICU stay >24 hours. Discharge (disch) patients included if in admission (adm) study part, surviving ≥24 hours after ICU disch Exclusion: patients transferred to another hospital, adm and disch same weekend period, patients unable to understand Dutch or English | 380 (203: 177) | Medicines-reconciliation (med rec) at care transitions (by ICU pharmacists); in patient rounds; combined with medication review (med rev) by pharmacist with ICU medical staff review to create ICU disch medication list. Medication advice included as supplement to the ward discharge letter. Discharge medication prepopulated on the ward electronic (e-) prescribing system (ICU adm, ICU stay, ICU disch) |
| Buckley et al USA[^55] | B-A; retrospective; single | De-escalation of inappropriate SUP | Adult ICU patients (≥18 years) Inclusion: all patients receiving acid suppressing therapy (AST) Exclusion: patients on AST, or diagnosis of GI disorders or admitted on AST. Patients in the emergency department, rehabilitation or psychiatric wards | 341 (174: 167) | SUP de-escalation programme (pharmacist-led authorised stress ulceration prescription management) (ICU stay, ward stay) |
| Coon et al USA[^56] | B-A; prospective; single | Med rec (of specific intravenous vasoactives) | Adult ICU patients (neurosurgery) Inclusion: all consecutive ICU patients transferred to the ward | 261 (130: 131) | Structured ICU handover checklist (incorporated into e-discharge documentation (by ICU medical staff)) (ICU disch) |
| D’Angelo et al USA[^57] | B-A; retrospective; single | De-escalation of inappropriate antipsychotics | Adult ICU patients (medical) Inclusion: all ICU patients initiated on antipsychotic therapy for ICU delirium ≥24 hours prior to ward transfer | 281 (140: 141) | Antipsychotic discontinuation bundle (education of medical, nursing and pharmacy staff; clinical guidelines (including non-pharmacological interventions and de-escalation based on delirium screening) (ICU stay) |
| Hammond et al USA[^58] | B-A; retrospective; single | De-escalation of inappropriate SUP | Adult ICU patients (medical) ≥18 years Inclusion: all patients prescribed AST Exclusion: diagnosis of GI bleed, receiving AST on ICU adm, or history of Zöllinger-Ellison syndrome | 219 (101: 118) | Educational interventions for SUP (education of ICU medical staff; guideline; pharmacist on ward rounds to support education) (ICU stay) |
| (B) Wohlt et al[^62] (A) Hatch et al[^69] USA | B-A; retrospective; single | De-escalation of inappropriate SUP | Adult ICU patients (medical, surgical) ≥18 years Inclusion: all ICU patients Exclusion: patients with a GI bleed, Zöllinger-Ellison syndrome, prison status or died in hospital | 750 (394: 356) | Education on SUP (education of ICU and ward medical and pharmacy staff; audit and feedback of preintervention results; guideline) (ICU stay, ward stay) |
| Heselmans et al Belgium[^14] | Randomised controlled trial; prospective; multi (n=3) | Drug-related problems in patients after ICU to ward transfer | ICU patients (medical, surgical) ≥15 years Inclusion: patients with ICU stay ≥3 days and transferred to surgical, medical or geriatric ward Exclusion: patients with a ‘do not resuscitate’ order | 600 (299: 301) | Medication review by ward-based pharmacists after ICU patient transfer (ward stay (<48 hours of ICU transfer)) |

Continued
| Study/Country | Study design/centres (number) | Intervention target | Participants | Participant numbers (control/after) | Intervention description, (components) and (timing) |
|---------------|-------------------------------|---------------------|--------------|-------------------------------------|--------------------------------------------------|
| Kram et al USA 60 | B-A; retrospective; single | De-escalation of inappropriate antipsychotics | Adult ICU patients (medical, surgical, cardiothoracics, neurosciences and cardiac) ≥18 years Inclusion: ICU patients with atypical antipsychotic prescribed in ICU Exclusion: patients had <2 antipsychotic doses in ICU on antipsychotics pre-ICU adm or non-delirium psychiatric indication, or if died in ICU | 358 (133: 225) | E-handover tool (prompting medication review by pharmacists (ICU and ward); supported by education (pharmacy staff), including audit and feedback of preintervention results) (ICU stay; ICU disch; ward stay) |
| Medlock et al Netherlands 57 | B-A; prospective; single | ICU e-disch letter (template included med rec details) | Adult ICU patients (medical, surgical) Inclusion: all critical care patients (discharged alive or dead) | 6823 (1872: 4951) | E-letter to ward medical staff and general practitioner (with template and automatic assignment to ICU medical staff) (ICU disch) |
| Meena et al USA 52 | B-A; retrospective; single | De-escalation of inappropriate SUP | Adult ICU patients Inclusion: ICU patients already taking AST on admission, therapeutic indication for AST, patients died within 24 hours of admission | 224 (106: 118) | Education sessions for medical staff (didactic education session for junior medical staff) (ICU stay) |
| Parsons Leigh et al Canada 50 | B-A; retrospective; single | ICU e-transfer tool with eight key elements (including active medicines and med rec) | Adult ICU patients (medical, surgical, neurosurgical and trauma) Inclusion: randomly selected cohort of ICU patients transferred to an inpatient ward Exclusion: ICU patients not transferred to an inpatient ward | 60 (30: 30) | E-transfer tool (auto-population of elements, eg, medicines to continue on ward transfer with facility to review and refine; facility to compare with preadmission med rec and identify changes (by medical staff)) (ICU disch) |
| Pavlov et al USA 49 | B-A; retrospective; single | De-escalation of inappropriate SUP and bronchodilators | Adult ICU patients (medical, surgical) Inclusion: ICU patients on acid blockers or bronchodilators Exclusion: patients who died during their adm or still in ICU on study data extraction | 454 (201: 253) | Med rec (on hospital adm (pharmacy technician) and ICU disch (ICU nurse), with medical staff confirmation and in reconciliation with medication on ICU disch) (ICU disch) |
| Pronovost et al USA 50 | Time-series analysis; prospective; single | MEs on ICU discharge | Adult ICU patients (surgical) Inclusion: random selection of 10–15 patients per week | No information | Med rec (by ICU nurses on patient adm and ICU disch. Specific MEs prompted discussion with ICU medical staff) (ICU adm, ICU disch) |
| Stuart et al USA 53 | B-A; retrospective; single | De-escalation of inappropriate antipsychotics | Adult ICU patients (medical, surgical, cardiac) Inclusion: ICU patients with antipsychotic prescribed for delirium Exclusion: palliative care or died, on antipsychotics pre-ICU adm, or non-delirium psychiatric indication | 158 (79: 79) | Pharmacist-led de-escalation protocol (de-escalation guideline with education of staff (ICU and ward pharmacists). Pharmacists authorised to discontinue or taper antipsychotics in ICU patients with resolved delirium symptoms) (ICU stay (direct patient disch), ward stay) |
| Tasaka et al USA 51 | B-A; retrospective; single | De-escalation of inappropriate SUP | Adult ICU patients (medical, surgical) Inclusion: all ICU patients Exclusion: patients requiring continued AST (eg, active GI bleed), or no indication for AST (eg, total gastrectomy) | 124 (74: 50) | SUP de-escalation bundle. Guideline, education of staff (medical, nurses, pharmacists, dietitians), multifaceted awareness campaign, pharmacist SUP recommendations (on care rounds, or by text/telephone) with documentation in e-medical notes. SUP not included in the e-prescribing core or ICU adm order sets (ICU disch) |
Systematic review

Seven studies included a specific medication review component within the intervention\(^1\)\(^\text{13}\)\(^\text{14}\)\(^\text{51}\)\(^\text{53}\)\(^\text{55}\)\(^\text{60}\) (table 1 and online supplemental table S1). Five of these studies included a pharmacist-led medication review as part of a multicomponent intervention targeted at a specific de-prescribing initiative, either of inappropriate SUP,\(^5\)\(^\text{51}\)\(^\text{54}\)\(^\text{55}\) or use of antipsychotics.\(^5\)\(^\text{60}\)

**Guidelines**
Six studies (35%) implemented a clinical guideline intervention component,\(^\text{51}\)\(^\text{53}\)\(^\text{54}\)\(^\text{57}\)\(^\text{59}\) four focused on de-escalation of inappropriate medication on transfer\(^\text{53}\)\(^\text{54}\)\(^\text{57}\) (table 1 and online supplemental table S1). Three studies had clear multiprofessional participation in the guideline development.\(^\text{51}\)\(^\text{57}\)\(^\text{58}\) Implementation of the clinical guidelines included education and awareness of staff in all studies.\(^\text{51}\)\(^\text{53}\)\(^\text{54}\)\(^\text{57}\)\(^\text{59}\)

**Medicines reconciliation**
Four studies investigated a medicines reconciliation intervention (table 1 and online supplemental table S1).\(^\text{13}\)\(^\text{49}\)\(^\text{50}\)\(^\text{52}\) The healthcare professionals undertaking the medication review varied, with pharmacist,\(^\text{13}\) pharmacy technician,\(^\text{49}\) ICU nurse,\(^\text{50}\) and ICU nurse with a pharmacist involved.\(^\text{52}\) All medicines reconciliation processes required review and authorisation by medical staff, with pharmacist medication review and advice also provided in the study by Bosma et al.\(^\text{13}\) Medicines reconciliation was undertaken on patient ICU admission and ICU discharge in all four studies.\(^\text{13}\)\(^\text{49}\)\(^\text{50}\)\(^\text{52}\) Bosma et al\(^\text{13}\) provided detailed information on the delivery and quality of medicines reconciliation on the interfaces of care.

**Electronic transfer/handover tool or letter**
Four studies\(^\text{48}\)\(^\text{56}\)\(^\text{60}\)\(^\text{61}\) implemented an intervention designed to improve communication from the ICU to the hospital ward and included a medication-related component (table 1 and online supplemental table S1). The communication was directed at a range of healthcare professionals: general practitioners,\(^\text{61}\) ICU and hospital ward pharmacists\(^\text{60}\) and hospital ward medical staff.\(^\text{48}\)\(^\text{56}\)

**Intervention timing**
There was a high degree of variation with regard to the timing of the intervention components delivered in the patient acute care pathway (table 1 and online supplemental table S1). Most (n=10, 59%) of studies investigated an intervention delivered at a single timepoint in the patient pathway.\(^\text{47}\)\(^\text{49}\)\(^\text{47}\)\(^\text{49}\)\(^\text{51}\)\(^\text{54}\)\(^\text{36}\)\(^\text{58}\)\(^\text{61}\) For five of these studies, this was during the ICU patient stay.\(^\text{47}\)\(^\text{51}\)\(^\text{54}\)\(^\text{57}\)\(^\text{58}\) which was also the period most interventions included (n=10, 59%).\(^\text{13}\)\(^\text{47}\)\(^\text{51}\)\(^\text{53}\)\(^\text{55}\)\(^\text{57}\)\(^\text{60}\) Eight studies (47%) also included the ICU discharge period in the intervention delivery.\(^\text{13}\)\(^\text{48}\)\(^\text{50}\)\(^\text{52}\)\(^\text{56}\)\(^\text{60}\)\(^\text{61}\)
Five studies included an intervention element that included the patient’s hospital ward stay,\citep{14,33,55,60} three of which included a medication review intervention component.\citep{14,33,60}

Facilitators and barriers to intervention delivery

Most studies (12, 71%) identified facilitators to the intervention delivery (Table 2).\citep{13,48,50,51,53,56,58,61} The availability of specialist ICU clinical pharmacists contributing to a range of activities including multidisciplinary ward rounds, staff education, medicines reconciliation, medication reviews and de-prescribing were highlighted in seven studies.\citep{13,51,53,55,58,59} Integration of the electronic transfer/handover tool or letter into existing electronic systems was reported as a facilitator in three studies,\citep{48,56,61} as was auto-population of data on transfer reports,\citep{48,59,61} and software tailoring.\citep{48,60,61} The important role of a supportive quality improvement organisational culture was emphasised in two studies.\citep{50,61}

Fewer studies (n=7, 41%) provided an indication of intervention barriers (Table 2).\citep{13,14,50,52,53,56,58} The most common barrier cited (n=3, 18%) was increased workload associated with the intervention.\citep{13,50,56} Multi-professional collaboration was reported as barrier to intervention delivery when limited,\citep{14} and a facilitator when effective.\citep{50,51}

Outcomes

Medication outcomes

We describe the medication outcomes according to the focus of the intervention on those outcomes.

There was sufficient de-prescribing medication outcome data from intervention studies to conduct a meta-analysis. A narrative synthesis of other medication outcome data and findings related to interventions
Systematic review

Table 2  Facilitators and barriers identified from the selected studies classified by system factors

| System factor | Facilitator/Barrier | Studies, n (%) |
|---------------|---------------------|----------------|
| Healthcare professionals | | |
| Clinical pharmacist availability | Facilitator | 7 (41%)13 51 53-55 58 59 |
| Multiprofessional collaboration | Both (facilitator when good collaboration, barrier when poor collaboration) | 3 (18%)14 50 51 |
| Staff perception of limited intervention value | Barrier | 2 (12%)52 56 |
| Off shift hours (eg, clinical pharmacists) | Barrier | 2 (12%)33 53 |
| Tasks | | |
| Pharmacist participation on ICU multiprofessional ward round | Facilitator | 4 (24%)13 51 58 59 |
| Increased workload associated with discharge intervention process (eg, medicines reconciliation, checklist) | Barrier | 3 (18%)13 50 56 |
| Structured approach to medicines reconciliation | Facilitator | 2 (12%)13 50 |
| Gaps in educational process | Barrier | 2 (12%)52 58 |
| Education package revised, condensed and delivered regularly | Facilitator | 1 (6%)51 |
| Focus on the care transition | Facilitator | 1 (6%)51 |
| Technologies and tools | | |
| Auto-population of discharge information from electronic health record | Facilitator | 3 (18%)48 50 61 |
| Checklist integrated into existing workflow/systems | Facilitator | 3 (18%)48 56 61 |
| Tailored discharge letter/tool software | Facilitator | 3 (18%)48 60 61 |
| Guideline and supporting documentation | Facilitator | 1 (6%)59 |
| Organisational conditions | | |
| Quality improvement culture | Facilitator | 2 (12%)10 61 |
| Task allocation | Both | 2 (12%)10 61 |
| Ability to initiate the summary on patient admission and edit throughout the ICU stay | Facilitator | 1 (6%)48 |
| Patient discharged from ICU out of hours | Barrier | 1 (6%)13 |
| Short discharge time-frame | Barrier | 1 (6%)13 |

ICU, intensive care unit.

with medicines optimisation, patient and economic evaluation outcomes are presented. Most studies used medical notes review for medication outcomes. A summary of the study outcomes and measures is shown online supplemental table S2.

**De-prescribing outcomes**

Eleven studies (65%) focused on de-escalation of inappropriate medication therapy on ICU discharge or at hospital discharge (table 1).47 49 51-55 57-60 the most common focus being the reduction of inappropriate SUP.57 51 52 54 55 58 59

**Medicines optimisation outcomes**

Interventions targeted on medicines optimisation outcomes had a much broader remit, examining the clinical effectiveness and safety of all the patient’s medicines, usually employing a combination of medicines reconciliation and medication review.63 Heselmans et al14 focused on a medication review intervention conducted in three Belgian hospitals by hospital pharmacists on the ward within 48 hours of the ICU patient transfer; 54.1% (203/375) of the drug-related problems (DRPs) were adjusted on time in the intervention group compared with 12.8% (47/368) in the control group. Compared with the control group, the odds of implementing a change in medication therapy recommendations in the intervention group were 10-fold higher (OR 10.1, 95% CI 6.3 to 16.1), increasing to OR 15.6 (95% CI 9.4 to 25.9), when between-group differences in types of DRPs were accounted for.

In a two-centre before-after study, Bosma et al13 investigated the effect of a medicines reconciliation intervention on discharge medication transfer errors (any unintentional discrepancy between the patient’s prescription chart and best possible ward medication list at 24 hours after discharge) (online supplemental table S2). On ICU discharge, 41.2% (73/177) of patients in the intervention period had at least one ME compared with 73.9% (150/203) of patients in the before phase. After correcting for baseline differences in patient severity of illness, patients in the intervention period had an adjusted OR 0.24 (95% CI 0.15 to 0.37) for a discharge ME.

**Documentation and communication outcomes**

Electronic transfer/handover tool or letters improved the timeliness of information transfer and completeness of information provision.48 61
Patient outcomes

Eight studies (47%) reported between-group comparison of patient outcomes (online supplemental table S2). No mortality difference was reported in the medication review RCT, or in one communication before-after intervention study. Two studies included an assessment of actual, or potential ADEs, with a significant reduction in the latter. The RCT investigating medication reviews, reported no differences between the intervention and control groups in any patient outcomes (mortality rate, ICU readmission rate or hospital length of stay). Three other studies reported no effect of the intervention on hospital length of stay.

Risk of bias and overall quality of evidence

Overall, the quality of the studies was low (online supplemental figures S1 and S2). All the non-randomised studies were assessed as moderate to serious RoB except one, which was graded as critical RoB and was excluded from the meta-analysis. The RCT by Heselmans et al was also assessed as high RoB due to the randomisation process domain.

The GRADE assessments for the overall quality of evidence for the main meta-analysis and subgroup analysis of studies focused on the de-escalation of inappropriate medication on ICU and hospital discharge are shown (online supplemental table S3).

Main meta-analysis

The meta-analysis was undertaken for interventions that had the common outcome of de-escalation of inappropriate medication (de-prescribing) at ICU and hospital discharge points (figure 2). Compared with the before period of usual care, pooled analysis of all interventions reduced the risk of inappropriate medication continuation at ICU discharge (OR=0.45 (95% CI 0.31 to 0.63), I²=55 (5–79) %, n=9 studies) and hospital discharge (OR=0.39 (95% CI 0.2 to 0.76), I²=75 (52–87) %, n=9 studies). There was no evidence of publication bias as indicated by funnel plot symmetry, and the non-significant Egger’s regression test (p=0.583) and trim-and-fill method (p=0.152) for the primary outcome (online supplemental figure S3). The quality of evidence for ICU discharge and hospital discharge points were considered low to very low, respectively (online supplemental table S3).

Subgroup analysis

Subgroup meta-analysis showed that multicomponent interventions (based on education of staff and guidelines) led to a reduction in inappropriate medication continuation at the hospital discharge point (OR=0.26 (95% CI 0.13 to 0.55), I²=67 (21–86) %, n=6 studies). There was an indication of benefit at ICU discharge, but this did not reach statistical significance (OR=0.5 (95% CI 0.22 to 1.11), I²=62 (0–87) %, n=4 studies) (figure 3). Quality of evidence was moderate at hospital discharge and low for the ICU transition point (online supplemental table S3). In contrast, single component interventions (education of staff, medicines reconciliation, medication review) demonstrated a reduction in inappropriate medication continuation at ICU discharge (OR=0.42 (95% CI 0.24 to 0.74), I²=60 (0–85) %, n=5 studies), but not hospital discharge (OR=0.77 (95% CI 0.16 to 3.74), I²=50 (0–86) %, n=3 studies) (education of staff, medicines reconciliation, electronic handover tool) (figure 3); quality of evidence was graded low and very low, respectively (online supplemental table S3). No
further subgroup analyses of medication review and medicines reconciliation interventions were undertaken given the small number of studies involving high levels of heterogeneity and imprecise data.

**DISCUSSION**

**Summary of main findings**

This systematic review has found that pooled analysis of specific interventions (education of staff, medication review, guidelines, medicines reconciliation, electronic handover tool) to reduce inappropriate medication continuation on ICU and hospital discharge were effective, with more than twice the likelihood of effective de-prescribing (low and very low quality of evidence). Multicomponent interventions based on education of staff and guidelines were associated with an almost fourfold higher rate of inappropriate medication discontinuation at hospital discharge compared with usual care, with moderate quality of evidence. Single component interventions (education of staff, medicines reconciliation, medication review) were twice as likely as usual care to reduce inappropriate medication continuation at ICU discharge only (shown by low quality of evidence).

Patient and economic evaluation outcomes were reported in a minority of studies. Only one study demonstrated a reduction in potential ADEs with an ICU medicines reconciliation intervention, also providing the most compelling health economic data. Structured electronic transfer/handover tool or letters both within ICU, and beyond ICU to the hospital ward and general practitioners, improved medication-related completeness and communication.

Successful delivery of complex interventions usually requires a combination of several factors including resources, education and training of staff. Medication review by hospital ward-based clinical pharmacists soon after ICU patient transfer was very effective in the reduction of clinically important DRPs, also providing the most compelling health economic data. Structured electronic transfer/handover tool or letters both within ICU, and beyond ICU to the hospital ward and general practitioners, improved medication-related completeness and communication.

Successful delivery of complex interventions usually requires a combination of several factors including resources, education and training of staff. Medication review by hospital ward-based clinical pharmacists soon after ICU patient transfer was very effective in the reduction of clinically important DRPs, also providing the most compelling health economic data. Structured electronic transfer/handover tool or letters both within ICU, and beyond ICU to the hospital ward and general practitioners, improved medication-related completeness and communication.

**Comparison with previous research**

The main meta-analysis results are consistent with a recent systematic review of pharmacy-supported interventions to reduce inappropriate continuation of SUP in patients after ICU and hospital discharge that reported similar effectiveness. However, our meta-analyses considered discontinuation of all potentially inappropriate medication and were unconstrained by interventions delivered by a single profession. Multicomponent de-prescribing interventions primarily consisted of policy-type (guidelines) and single intervention functions (education (and training) of staff), sometimes supported by audit and feedback, to affect staff behaviour change and likely intervention adoption. This combination re-enforces information and desired practice, which have been reported to be effective in changing healthcare staff behaviours in de-prescribing interventions. A recent systemic review of medication-related interventions delivered in hospital and following discharge reported that the size of the treatment effect increased with the intensity (factoring number and repetition of components) of medication-related intervention delivered. However, such intervention intensity needs to be balanced with routine deliverability.

The identified facilitators and barriers to medication-related interventions are consistent with, and add further specific detail to, those already identified in other wider reviews of interventions to improve ICU patient continuity of care. These facilitators and barriers should inform the development and implementation of medication outcome interventions, particularly when staff behaviour change across different professions and teams is required.

**Strengths and limitations**

This systematic review had several strengths including multidisciplinary team expertise, comprehensive searches, detailed critical appraisal of the studies and presentation of different study elements. However,
there are also limitations. The conclusions are limited by the availability of study designs (uncontrolled before-after) employed, with inherent RoB that was mainly due to baseline confounding risks. We did not have sufficient studies to undertake a sensitivity analysis to examine the impact of the RoB assessment, although since the vast majority of studies were high risk, a sensitivity analysis is very unlikely to show any different findings. The meta-analysis was limited to a subgroup outcome of medicines optimisation, that is, de-prescribing of SUP, antipsychotics and bronchodilators. Wider de-prescribing foci are required, for example, opioid analgesia, to address the risk of inappropriate long-term continuation.19 Although studies used similar definitions for the respective outcomes of multiple inappropriate medications, as well as use of patient chart reviews, there are still significant inconsistencies in terms of design and exact methods. We were unable to describe the intervention mechanisms of action as most studies neglected to provide process evaluation elements.

Implications for policy and practice
Intervention to reduce medication-related harm for patients on transitions of care is a policy and practice priority,3 being particularly pertinent to the complexity of acutely ill patient care transition to a hospital ward.75 Our findings suggest that multicomponent interventions, including education of staff and guidelines, are promising in reducing inappropriate continuation of acute medication by hospital discharge (moderate quality of evidence). It seems reasonable to consider routine adoption of these low-risk and likely low-cost interventions. However, further research is required on how best to improve the more challenging medicines optimisation aspect, re-introduction of clinically important chronic medication, for ICU patients transferring to the ward and beyond. To inform this research, consensus on the key medication-related interventions to use and what medication and patient outcomes measures to test these against, as well as how the human factors involved in medication transfer errors can be addressed are required. The resulting intervention is likely to be a theory-informed multi-component intervention that should be evaluated in a multicentre cluster or stepped-wedge RCT that includes a health economic evaluation. Process evaluation capable of informing the complex intervention mechanism of action and theory is also needed. In turn, this would support the implementation and delivery of practice and future policy recommendations.76

CONCLUSIONS
This systematic review and meta-analysis newly identified that interventions aimed at reducing inappropriate medication continuation on patient ICU discharge and hospital discharge increased de-prescribing efficacy. Multicomponent interventions, built on education of staff and guidelines, appeared most effective in reducing inappropriate medication by hospital discharge. However, none of the de-prescribing initiatives exhibited beneficial effects on patient outcomes. More complex interventions such as medication review and medicines reconciliation, targeted at reducing MEs and medication-related problems on ICU discharge, were very effective and reduced potential ADEs. Our findings highlight the need to improve the quality and design of future prospective randomised intervention studies in this area.

Author affiliations
1Pharmacy and Critical Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
2School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
3National Institute for Health Research (NIHR) Greater Manchester Patient Safety Translational Research Centre (PSTRC), School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
4National Institute for Health Research (NIHR) School for Primary Care Research, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK
5School of Health and Related Sciences (SchARR), The University of Sheffield, Sheffield, UK

Acknowledgements RSB would like to acknowledge the advice and expertise of Professor Danny Hind (Professor of Evaluation, School of Health and Related Research, The University of Sheffield) in the early methodological planning of the systematic review. All figures and tables are created by the authors.

Contributors RSB was responsible for the conception of this systematic review. RSB, DMA and MP contributed to study design and data interpretation. AS and RSB designed the search strategy. RSB and JKJ were responsible for writing the manuscript. RSB and JKJ performed data acquisition, analysis and interpretation of the findings. AH conducted the statistical data analysis and interpretation of the results. All authors contributed to, read and approved the final manuscript. RSB is the guarantor.

Funding This report is independent research supported by the National Institute for Health Research HEE/NIHR ICA Programme Clinical Lectureship, Dr Richard Bourne, NIHR300444. MP and DMP are funded by the National Institute for Health Research Greater Manchester Patient Safety Translational Research Centre (NIHR Greater Manchester PSTRC).

Disclaimer The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study does not involve human participants.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims...
all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID ID
Richard S Bourne http://orcid.org/0000-0003-0893-325X

REFERENCES
1. Fray M, Waterson P, Carman E. Care transitions in healthcare: The ‘high-hanging fruit’. *Appl Ergon* 2021;95:103437.
2. Aase K, Waring J. Crossing boundaries: establishing a framework for researching quality and safety in care transitions. *Appl Ergon* 2020;89:103228.
3. Donaldson LJ, Kelley ET, Dhingra-Kumar N, et al. Medication without harm: who’s third global patient safety challenge. *Lancet* 2017;389:1680–1.
4. World Health Organization. Medication safety in transitions of care, 2019. Available: https://www.who.int/publications/i/item/WHO-UCS-SDS-2019.9
5. Stelfox HT, Lane D, Boyd JM, et al. A scoping review of patient discharge from intensive care: opportunities and tools to improve care. *Chest* 2015;147:317–27.
6. Hua M, Wunsch H. The complexities of ICU discharge. *Chest* 2015;147:281–2.
7. Brown SM, Bose S, Banner-Goodspeed V, et al. Approaches to addressing Post-Intensive care syndrome among intensive care unit survivors. A narrative review. *Ann Am Thorac Soc* 2019;16:947–56.
8. Bell CM, Rahimi-Darabad R, Orner AL. Discontinuity of chronic medications in patients discharged from the intensive care unit. *J Gen Intern Med* 2006;21:937–41.
9. Campbell AJ, Bloomfield R, Noble DW. An observational study of changes to long-term medication after admission to an intensive care unit. *Anaesthesia* 2006;61:1087–92.
10. Bourne RS, Ioannides CP, Gillies CS, et al. Clinical frailty and polypharmacy in older emergency critical care patients: a single-centre retrospective case series. *Eur J Hosp Pharm* 2021. doi:10.1136/ehjpharm-2020-002618. [Epub ahead of print: 02 06 2021].
11. Royal Pharmaceutical Society. Polypharmacy: getting our medicines right. London, 2019. Available: https://www.rpharms.com/implementation/setting-professional-standards/polypharmacy-getting-our-medicines-right
12. Bosma BE, Hunfeld NGM, Roobol-Muëwese E, et al. Voluntarily reported prescribing, monitoring and medication transfer errors in intensive care units in the Netherlands. *Int J Clin Pharm* 2021;43:3.
13. Bosma LBE, Hunfeld NGM, Quax RAM, et al. The effect of a medication reconciliation program in two intensive care units in the Netherlands: a prospective intervention study with a before and after design. *Ann Intensive Care* 2018;8:19.
14. Heselmans A, van Krieken J, Cootjans S, et al. Medication review by a clinical pharmacist at the transfer point from ICU to ward: a randomized controlled trial. *J Clin Pharm Ther* 2015;40:578–83.
15. Tully AP, Hammond DA, Li C, et al. Evaluation of medication errors at the transition of care from an ICU to Non-ICU location. *Crit Care Med* 2019;47:543–9.
16. Sauro KM, Soo A, de Grood C, et al. Adverse events after transition from ICU to hospital ward: a multicenter cohort study. *Crit Care Med* 2020;48:946–53.
17. Scales DC, Fischer HD, Li P, et al. Unintentional continuation of medications intended for acute illness after hospital discharge: a population-based cohort study. *J Gen Intern Med* 2016;31:196–202.
18. Bell CM, Brener SS, Gunraj N, et al. Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. *JAMA* 2011;306:840–7.
19. MacTavish P, Quasim T, Purdie C, et al. Medication-Related problems in intensive care unit survivors: learning from a multicenter program. *Ann Am Thorac Soc* 2020;17:1326–9.
20. Stollings JL, Bloom SL, Wang L, et al. Critical care pharmacists and medication management in an ICU recovery center. *Ann Pharmacother* 2018;52:713–23.
21. Bosma LBE, van Rein N, Hunfeld NGM, et al. Development of a multivariable prediction model for identification of patients at risk for medication transfer errors at ICU discharge. *PLoS One* 2019;14:e0215459.
22. Turnbull AJ, Donaghy E, Salisbury L, et al. Polypharmacy and emergency readmission to hospital after critical illness: a population-level cohort study. *Br J Anaesth* 2021;126:415–22.
23. Rhodes A, Moreno R, Azoulay E, et al. Prospectively defined indicators to improve the safety and quality of care for critically ill patients: a report from the task force on safety and quality of the European Society of intensive care medicine (ESICM). *Intensive Care Med* 2012;38:598–605.
24. van Sluisveld N, Bakhshi-Raize F, de Keizer N, et al. Variation in rates of ICU readmissions and post-ICU in-hospital mortality and their association with ICU discharge practices. *BMJ Health Serv Res* 2017;17:281.
25. Bourne RS, Shulman R, Jennings JK. Reducing medication errors in critical care patients: pharmacist key resources and relationship with medicines optimisation. *Int J Pharm Pract* 2018;26:534–40.
26. Stelfox HT, Leigh JP, Dodek PM, et al. A multi-center prospective cohort study of patient transfers from the intensive care unit to the hospital ward. *Intensive Care Med* 2017;43:1485–94.
27. Taylor SB, Chou S-H, Sierra ME, et al. Association between adherence to recommended care and outcomes for adult survivors of sepsis. *Ann Am Thorac Soc* 2020;17:89–97.
28. Prescott HC, Angus DC. Enhancing recovery from sepsis: a review. *JAMA* 2018;319:62–75.
29. Singh-Franco D, Mastropietro DR, Metzner M, et al. Impact of pharmacy-supported interventions on proportion of patients receiving non-indicated acid suppressive therapy upon discharge: a systematic review and meta-analysis. *PLoS One* 2020;15:e0243134.
30. Page MJ, McKenzie JE, Bossuyt PM, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. *J Clin Epidemiol* 2021;134:103–12.
31. Cochrane Effective Practice and Organisation of Care Group. What study designs should be included in an EPOC review and what should they be called? Available: http://epoc.cochrane.org/sites/epoc.cochrane.org/files/public/uploads/EPOC Study Designs About.pdf
32 Parker JT, Barton JL, Mee H. Quality of ICU patient discharge medication review: Effect of a mandatory discharge checklist. In: Intensive care Society, state of the art meeting, London, 2018.

33 Record J, Oszkinis T, Weaver ECC. Goals of care information rarely documented for critically ill patients even after a brief educational intervention. Journal of General Internal Medicine 2018;S704–5.

34 Schwartz A, Giancarelli A, Liu-DeRyke X. Impact of trauma pharmacists on the management of pain, agitation, and delirium after ICU discharge. Crit Care Med 2019;47:865.

35 Martz C, Peters M, Swiderek J, et al. 962: evaluation of a PHARMACIST-DRIVEN medication discontinuation protocol in an intensive care unit. Crit Care Med 2018;46:464.

36 Hanks F, Jones C. Pharmacist medicines optimisation and error mitigation at critical care discharge–a human solution to an electronic risk. In: Journal of the Intensive Care Society, 2019: 91–2.

37 Sterne JAC, Savović J, Page MJ, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.

38 Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919.

39 Langendam MW, Alié EA, Dahn B, et al. Assessing and presenting summaries of evidence in Cochrane reviews. Syst Rev 2013;2:81.

40 Hoffmann TC, Glaziou PB, Broutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014;348:g1687.

41 Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med 1987;6:341–8.

42 IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 2014;14:25.

43 Higgins JPT, Thomas J, Chandler J. Cochrane Handbook for systematic reviews of interventions, 2019. Available: www.training.cochrane.org/handbook

44 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629.

45 Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 2019;22:153–60.

46 Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J Stat Softw 2010;36:1–48.

47 Meena N, Costner M, Joshi M. Stress ulcer prophylaxis use in the intensive care unit before and after house staff education. J Ark Med Soc 2015;112:38–40.

48 Parsons Leigh J, Brundin-Mather R, Zdajewicz K, et al. Improving transitions in care from intensive care units: development and pilot testing of an electronic communication tool for healthcare providers. J Crit Care 2020;56:265–72.

49 Pavlov A, Muravyev R, Moaoteng-Adjpong Y, et al. Inappropriate discharge on bronchodilators and acid-blocking medications after ICU admission: importance of medication reconciliation. Respir Care 2014;59:1524–9.

50 Pronovost P, Weast B, Schwarz M, et al. Medication reconciliation: a practical tool to reduce the risk of medication errors. J Crit Care 2003;18:201–5.

51 Tasaka CL, Burg C, VanOsdl SJ, et al. An interprofessional approach to reducing the overutilization of stress ulcer prophylaxis in adult medical and surgical intensive care units. Ann Pharmacother 2014;48:462–9.

52 Zeigler AJ, Mcallen KJ, Slot MG, et al. Medication reconciliation effect on prolonged inpatient stress ulcer prophylaxis. Ann Pharmacother 2008;42:940–6.

53 Stuart MM, Smith ZR, Payter KA. Pharmacist-driven discontinuation of antipsychotics for ICU delirium: a quasi-experimental study. J Am Coll Clin Pharm 2020;3:1009–14.

54 Anstey MH, Litton E, Palmer RN, et al. Clinical and economic benefits of de-escalating stress ulcer prophylaxis therapy in the intensive care unit: a quality improvement study. Anaesthesia Intensive Care 2019;47:503–9.

55 Buckley MS, Park AS, Anderson CS, et al. Impact of a clinical pharmacist stress ulcer prophylaxis management program on inappropriate use in hospitalized patients. Am J Med 2015;128:905–13.

56 Coon EA, Kramer NM, Fabris RR, et al. Structured handoff checklists improve clinical measures in patients discharged from the neurointensive care unit. Neurrol Clin Pract 2015;5:42–9.

57 D’Angelo RG, Rincavage M, Tata AL, et al. Impact of an antipsychotic discontinuation bundle during transitions of care in critically ill patients. J Intensive Care Med 2019;34:40–7.

58 Hammond DA, Killingsworth CA, Painter JT, et al. Impact of targeted educational interventions on appropriateness of stress ulcer prophylaxis in critically ill adults. Pharm Pract 2017;15:1–6.

59 Hatch JB, Schulz L, Fish JT. Stress ulcer prophylaxis: reducing non-indicated prescribing after hospital discharge. Ann Pharmacother 2010;44:1563–71.

60 Kram BL, Schultheiss JM, Kram SJ, et al. A Pharmacy-Based electronic handoff tool to reduce discharge prescribing of atypical antipsychotics initiated in the intensive care unit: a quality improvement initiative. J Pharm Pract 2019;32:434–41.

61 Medlock S, Eslami S, Askari M, et al. Improved communication in post-ICU care by improving writing of ICU discharge letters: a longitudinal before-after study. BMJ Qual Saf 2011;20:967–73.

62 Wohlt PD, Hansen LA, Fish JT. Inappropriate continuation of stress ulcer prophylactic therapy after discharge. Ann Pharmacother 2004;41:1611–6.

63 National Institute for Health and Clinical Excellence. Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes. NICE guideline NG5, 2015. Available: www.nice.org.uk/guidance/ng5%0Ahttps://www.nice.org.uk/guidance/ng5/chapter/1-recommendations

64 Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions: medical Research Council guidance. BMJ 2015;350:h1258.

65 Eitells F, Fernandes O. Medication reconciliation: ineffective or hard to implement? BMJ Qual Saf 2018;27:947–9.

66 van Suijsel N, Zegers M, Natsch S, et al. Medication reconciliation at hospital admission and discharge: insufficient knowledge, unclear task reallocation and lack of collaboration as major barriers to medication safety. BMC Health Serv Res 2012;12:170.

67 Vollam S, Dutton S, Lamb S, et al. Out-Of-Hours discharge from intensive care, in-hospital mortality and intensive care readmission rates: a systematic review and meta-analysis. Intensive Care Med 2018;44:1115–29.
68 Hervé MEW, Zucatti PB, Lima MADD, et al. Transition of care at discharge from the intensive care unit: a scoping review. Rev Lat Am Enfermagem 2020;28:1–14.
69 Tomlinson J, Cheong V-L, Fylan B, et al. Successful care transitions for older people: a systematic review and meta-analysis of the effects of interventions that support medication continuity. Age Ageing 2020;49:558–69.
70 Mitchell ML, Coyer F, Kean S, et al. Patient, family-centred care interventions within the adult ICU setting: an integrative review. Aust Crit Care 2016;29:179–93.
71 Michie S, Atkins L, West R. The Behaviour Change Wheel: A Guide to Designing Interventions. Sutton: Silverback Publishing, 2014.
72 Hansen CR, O’Mahony D, Kearney PM, et al. Identification of behaviour change techniques in deprescribing interventions: a systematic review and meta-analysis. Br J Clin Pharmacol 2018;84:2716–28.
73 van Sluisveld N, Oerlemans A, Westert G, et al. Barriers and facilitators to improve safety and efficiency of the ICU discharge process: a mixed methods study. BMC Health Serv Res 2017;17:251.
74 Atkins L, Francis J, Islam R, et al. A guide to using the theoretical domains framework of behaviour change to investigate implementation problems. Implement Sci 2017;12:77.
75 Urquhart A, Yardley S, Thomas E, et al. Learning from patient safety incidents involving acutely sick adults in hospital assessment units in England and Wales: a mixed methods analysis for quality improvement. J R Soc Med 2021;1:1–12.
76 Improved Clinical Effectiveness through Behavioural Research Group (ICEBeRG). Designing theoretically-informed implementation interventions. Implement Sci 2006;1:4.
77 Carayon P, Wooldridge A, Hoonakker P, et al. SEIPS 3.0: Human-centered design of the patient journey for patient safety. Appl Ergon 2020;84:103033.